

## AMENDMENTS TO THE CLAIMS

Please amend the claims as shown below. This listing of claims will replace all prior versions, and listing of claims in the application:

### Listing of Claims

1. (Currently amended)     ~~An isolated or purified~~ A pure peptide consisting of an amino acid sequence of SEQ ID NO.1 comprising an  
~~Isoleucyl-valyl-threonyl-asparaginyI-threonyl-threonine peptide.~~
2. (Canceled)
3. (Currently amended)     The peptide of Claim 1 2, wherein said peptide reduces the symptoms of a viral disease.
4. (Previously presented)   The peptide of Claim 3, wherein said viral disease is hepatitis B infection.
5. (Previously presented)   The peptide of Claim 1, wherein said peptide has immuno-stimulating properties.
6. (Canceled)
7. (Canceled)
8. (Currently amended)     A pharmaceutical composition comprising a pure peptide consisting of an amino acid sequence of SEQ ID NO.1 comprising an  
~~Isoleucyl-valyl-threonyl-asparaginyI-threonyl-threonine peptide.~~
9. (Canceled)
10. (Currently amended)    A method of making a pharmaceutical composition comprising providing a pure peptide consisting of an amino acid sequence of SEQ ID NO.1; an ~~Isoleucyl-valyl-threonyl-asparaginyI-threonyl-threonine peptide~~ and admixing said peptide with a pharmaceutically acceptable carrier.
11. (Currently amended)    A method of reducing the effects of a human disease comprising administering a pharmaceutically effective dose of a pure peptide

- ~~consisting of an amino acid sequence of SEQ ID NO.1 an-~~  
~~Isoleucyl-valyl-threonyl-asparaginyI-threonyl-threonine peptide.~~
12. (Previously presented) The method of Claim 11, wherein said human suffers from a viral disease.
13. (Previously presented) The method of Claim 12, wherein said viral disease is hepatitis B infection.
14. (Currently amended) A method of stimulating the immune system of an individual comprising administering a pharmaceutically effective dose of a pure peptide consisting of an amino acid sequence of SEQ ID NO.1 an-  
Isoleucyl-valyl-threonyl-asparaginyI-threonyl-threonine peptide.
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Newly added) The method of claim 14, wherein said peptide is administered with a food supplement.
22. (Newly added) The method of Claim 21, wherein said peptide is administered as a nutritional formulation further comprising a pharmaceutically or biologically acceptable carrier.
23. (Newly added) The method of Claim 11, wherein said peptide is administered intravenously, intraarterially, intramuscularly, topically, intracutaneously, subcutaneously, intradermally, transdermally, orally or by inhalation.
24. (Newly added) The method of Claim 14, wherein said peptide is administered intravenously, intraarterially, intramuscularly, topically,

intracutaneously, subcutaneously, intradermally, transdermally, orally or by  
inhalation.